Rebuilding American Manufacturing Event
The decades-old dictum of “innovate here, produce there” has stymied our nation’s technological progress and prowess. As Japan, Germany, Korea, Taiwan, and China have realized the benefits of “manufacturing-led” innovation systems, our nation, without innovative methods to produce newly developed technology, has failed to reap the benefits from our investments in R&D.
Our roundtable of senior leadership at the White House National Economic Council and U.S. Dept. of Health and Human Services as well as a diversity of viewpoints across political ideologies from Breakthrough Energy, American Compass, MIT’s The Engine, and Employ America discussed competing with China on advanced manufacturing sectors (bioeconomic, semiconductor, quantum, etc.), supply chain resilience, and new visions for industrial policy that can stimulate regional development.
By providing essential funding mechanisms, the Bioeconomy Finance Program will reduce the risks inherent in biotechnology innovation, encouraging more private sector investment.
While the U.S. has made significant advancements and remained a global leader in biotechnology over the past decade, the next four years will be critical in determining whether it can sustain that leadership.
It’s paramount to balance both innovation capabilities and risk as we work towards ensuring that the U.S. bioeconomy is a priority area for both the Nation and for National Security.
The Federation of American Scientists supports the National Security Commission on Emerging Biotechnology’s Final Report and the Recommendations contained within it.